Recent Updates
Recently added Catalysts
PSNL Positive Sentiment

Personalis Reports Second Quarter Results and Recent Highlights

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Personalis, Inc. reported its second quarter results for 2026, showcasing significant achievements, including the receipt of Medicare coverage for its NeXT Personal immunotherapy monitoring service. This coverage is aimed at patients with late-stage solid tumors, reflecting the company's commitment to enhancing precision oncology. The report highlights operational successes that may position Personalis for future growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • Secured Medicare coverage for NeXT Personal.
  • Focus on advanced genomics for precision oncology.
  • Recent business accomplishments indicate growth.

Full Press Release Details

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments. Second Quarter and Recent Strategic and Operational Highlights Secured Medicare Coverage for IO Monitoring: Received Medicare coverage approval for NeXT Personal for immunotherapy monitoring for patients with late-stage solid tumors. Se

Frequently Asked Questions

What were the highlights of Personalis' Q2 results?

Personalis reported significant achievements, including Medicare coverage for NeXT Personal.

What is NeXT Personal used for?

NeXT Personal is used for immunotherapy monitoring in patients with late-stage solid tumors.

When did Personalis report its Q2 results?

Personalis reported its Q2 results for the year ending June 30, 2026.

What is the focus of Personalis, Inc.?

Personalis focuses on advanced genomics for precision oncology.

ShareAdd on Google
Tags: PSNL Viatris Investor Conferences Healthcare Personalis Medicare coverage NeXT Personal oncology
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$233M liquidity · $7M/mo burn
~28 mo
Minimal dilution risk